Dry Eye Syndrome Therapeutics Analysis, Clinical Trials and Developments

Dry eye syndrome therapeutics currently exhibits a proliferating pipeline of 50+ therapeutic candidates.

According to the research, most of the therapeutic drug candidates are being developed for topical administration. It has been found that topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction, and therefore, improves patient compliance.

The companies who are involved in developing therapeutics for dry eye syndrome have shown positive clinical results in the various phases of drug development. For instance, HL036, an anti- tumor necrosis factor (TNF) biobetter antibody, is being developed by HanAll BioPharma in collaboration with Harbour BioMed for the treatment of inflammatory diseases. The results from the Phase II clinical trials of the drug candidate, showed statistically significant improvement of the symptoms, in the patients with dry eye syndrome.

Moreover, in September 2017, Redwood Pharma AB contracted the Swiss contract research organization (CRO) CROss Alliance for the management of a clinical Phase II clinical trial of the drug candidate, RP101, in patients with chronic dry eye disease.

TopiVert Pharma Limited, Redwood Pharma AB, HanAll BioPharma, Takeda Pharmaceutical Company Limited, Mitotech SA, Harbour BioMed, and Samjin Pharm Co. Ltd. are some of the key companies involved in the development of dry eye syndrome therapeutics.

Read more: https://www.pharmaproff.com/report/dry-eye-syndrome-therapeutics-pipeline-analysis

Read More

Psoriasis Therapeutics Analysis, Clinical Trials and Developments

Psoriasis is identified as a condition which causes chronic inflammation and scaling on skin. It develops when skin cells grow rapidly below the surface of the skin and get deposited on the surface before they get matured. In general, this deposition of cells takes a month time however, in psoriasis it may occur within few days. Development of thick patches of inflamed skin with a silvery scale covering starts to appear on skin. These patches are also referred to as plaques as they itch and feel sore. The commonly affected areas are knees, elbows, other parts of the legs, lower back, scalp, soles of feet, face and palms. Psoriasis can also affect toenails, fingernails, inside the mouth and soft tissues of genitals. The most common types of psoriasis are plaque psoriasis, inverse psoriasis, and pustular psoriasis. The disease is generally diagnosed using a skin biopsy.

Currently, there is no cure for psoriasis; however, there are several symptomatic treatment options available to improve the quality of life of patients. These medical options include topical treatment (corticosteroids, retinoids, and vitamin D analogs), phototherapy (ultraviolet B and photochemotherapy), and systemic medication (methotrexate, acitretin, cyclosporine, etanercept, and infliximab). Moreover, lifestyle modifications, such as diet and alternative therapies are also common components of psoriasis treatment regimens.

Pre-Purchase Inquiry at: https://www.pharmaproff.com/enquiry/1248

According to the research findings, majority of the pipeline drug candidates are being developed for topical administration. It has been found that the topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction, and thus, improves patient’s compliance toward medications for the treatment of the disease.

In January 2018, Monash University collaborated with Janssen Global Services LLC (a subsidiary of Johnson & Johnson) to investigate factors that lead to immune-mediated disease, psoriasis, and discover new treatments for the disease prevention. Therefore, by leveraging the Monash University’s technological capabilities, the company extended a three-year research program for the development of various novel approaches for the treatment of autoimmune disease. Moreover, in September 2015, NuMedii Inc. collaborated with Allergan plc to explore new therapeutic options for the treatment of psoriasis.

Novartis AG, AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Pfizer Inc., Johnson & Johnson, and LEO Pharma A/S are some of the major key players involved in the development of psoriasis therapeutics.

Read More